Last updated: July 27, 2026
Hydroxyprogesterone caproate (HPC), brand name Makena (AMAG Pharmaceuticals), has no active, FDA-approved clinical-trial pathway to preserve market authorization after the confirmatory FDA demand was met by an unfavorable trial outcome. Market access is constrained to remaining, grandfathered commercial supply in the US and any authorized rebranded equivalents under state-by-state and federal pharmacy distribution realities. Generic entry is still constrained primarily by FDA regulatory posture and product-specific IP/label barriers, not by broad “open” pathway assumptions.
This page consolidates the clinical trial record, the market outcome, and a projection framework centered on FDA status, exclusivity, and generic/biosimilar-like analog risk (HPC is a small molecule). Patent-expiration-driven commercialization planning is included only where enforceable listings are tied to the Makena product authorization record.
What is hydroxyprogesterone caproate (HPC) and what is the current FDA regulatory status?
HPC is a synthetic progestin administered to prevent recurrent preterm birth in patients with a prior spontaneous preterm birth. Makena was the long-standing branded option in the US. The clinical justification for the indication was revisited through FDA’s confirmatory requirement after early studies supported efficacy.
FDA approval context and label
- Indication history centered on preventing recurrent preterm birth in singleton pregnancies with a prior spontaneous preterm birth.
- Regulatory inflection occurred after confirmatory evidence failed to show the expected benefit.
Key regulatory outcome
- The confirmatory trial results led to Makena’s withdrawal of approval from the market (US), with FDA action tied to efficacy confirmation.
(Note: The clinical and regulatory outcome drives current market access more than any remaining patents do.)
Which clinical trial updated evidence changed hydroxyprogesterone caproate’s market outcome?
The market outcome is anchored to the confirmatory study that did not replicate earlier efficacy signals.
Confirmatory trial that drove FDA action
PROLONG trial (NCT01024342)
- Patient population: women with prior spontaneous preterm birth.
- Endpoint: reduction in recurrent preterm birth.
- Result: no statistically significant reduction versus control for the primary clinical endpoint, undermining the basis for continued approval.
Regulatory consequence
- FDA required and evaluated confirmatory data.
- The negative confirmatory evidence supported withdrawal/ending of the approval basis for the original indication.
Earlier efficacy signals
- Earlier trials suggested a reduction in recurrence of preterm birth, creating the basis for earlier approval and premium pricing.
- PROLONG created the “version change” from early promise to the current US market status.
What is the hydroxyprogesterone caproate clinical trials pipeline status now?
There is no widely recognized, FDA-ready confirmatory replacement program that reopens the prior US approval foundation for recurrent preterm birth prevention using HPC in the same label form.
What types of studies are likely, but not assumed
- New trial programs would need a clear endpoint strategy and a patient selection or formulation differentiation that can re-establish clinical benefit.
- Any attempt to re-enter the market through a new indication would still face a benefit-risk hurdle and likely require robust Phase 3 evidence.
(For current commercial projection, the key fact is the absence of a new, approved label pathway that would reset market demand.)
What patents protect hydroxyprogesterone caproate (Makena) and how many are in the US patent estate?
Patent planning must be grounded in the Orange Book and the underlying US patent family tied to Makena. For HPC, the commercial reality is that FDA approval status and label termination drive demand more quickly than patent term.
How to read the estate for HPC commercialization
- Drug substance patents typically cover progestin chemistry, intermediates, and stereochemistry.
- Product and formulation patents cover administration-specific characteristics (vehicle, stability, delivery performance).
- Method-of-use patents cover the prior-preterm-birth prevention regimen.
Commercial implication
Even with remaining unexpired patents in theory, commercialization depends on:
- FDA authorization for marketing,
- label scope,
- exclusivity/conditions tied to the NDA,
- enforcement risk from active Orange Book-listed patents.
Because the central indication approval basis was withdrawn or ended, the “effective exclusivity window” is shorter than a strict patent-expiration count would suggest.
What is the Orange Book status of Makena (hydroxyprogesterone caproate)?
Orange Book status is the gating layer for generic entry against a specific NDA/NDC.
Practical interpretation for market projection
- If Makena is not actively marketed under a continuing approved indication, generic incentives weaken because there is limited shelf positioning.
- If any reauthorized or alternative arrangements exist, the availability of listings and relevant patent numbers determines Paragraph IV feasibility.
(A complete Orange Book listing table is not included here because the task requires exact, product-tied patent numbers and expiry dates, and providing them without validated listings would reduce decision-grade usefulness.)
When does hydroxyprogesterone caproate lose exclusivity in the US?
If exclusivity is measured by patent and Orange Book timing alone, there can be a gap between legal exclusivity end and practical commercial re-entry.
Projectable driver
- FDA approval withdrawal/end of the indication typically eliminates the commercial base case earlier than patent term.
Result: for investors and R&D planners, the usable exclusivity horizon is dominated by FDA authorization status and label.
Will generics enter hydroxyprogesterone caproate and what Paragraph IV risks exist?
Paragraph IV framework
A typical Paragraph IV strategy depends on:
- an existing reference product with an active FDA-approved indication and Orange Book listings,
- availability of a viable generic regulatory pathway (ANDA),
- manageable risk of injunction or damages tied to listed patents.
HPC-specific commercial incentive
Given the label/evidence outcome, even a generic applicant may face:
- weaker reimbursement demand,
- limited prescriber adoption,
- limited ability to establish a meaningful market even if the product is technically generically manufacturable.
How does hydroxyprogesterone caproate compare with alternatives for preventing recurrent preterm birth?
Market substitution is the central competitive determinant after Makena’s clinical reversal.
Competitive substitution types
- Other progestins and alternative strategies assessed in preterm birth prevention
- Non-hormonal preventive approaches used depending on maternal risk strata
- Risk-based interventions guided by updated clinical guidelines
Business projection impact
- HPC demand declines when guidelines shift away from HPC as a recommended prevention strategy.
- Even if generic supply exists, substitution can keep utilization low.
What is the market size and revenue exposure for hydroxyprogesterone caproate, and how does it trend?
Market exposure drivers
- Guideline and payer coverage alignment
- FDA label restrictions or withdrawal effects
- Prescriber confidence after confirmatory data
- State formulary and reimbursement changes
Projection direction
- Base case: continued contraction in the US market after regulatory action.
- Upside case requires a new approved indication or strong evidence for revised patient selection with HPC or a differentiated formulation.
(A quantified revenue forecast is not included because the required commercial baseline and valid US channel figures for HPC are not provided in this prompt; decision-grade projections would be misleading without a verified starting point.)
What manufacturing and supply constraints exist for hydroxyprogesterone caproate re-entry?
Supply realities
- HPC is a sterile injectable with stability and fill-finish requirements.
- Any generic or reintroduction must meet sterile manufacturing quality, validated stability, and bioanalytical comparability.
Regulatory reality
- If the original indication is not approved, commercial supply becomes more niche.
- Any replacement would need to clear FDA approval for the relevant label.
What patent litigation affects hydroxyprogesterone caproate and what is the settlement risk profile?
Patent litigation risk affects generics more than it affects off-label or off-indication use, but HPC’s market is primarily driven by FDA label posture.
Litigation relevance
- Injunction leverage depends on active Orange Book patents tied to an approved NDA.
- Damages exposure depends on timing and infringement findings.
(A litigation table with docket numbers and outcomes is not included because exact case identifiers and outcomes must be validated to maintain decision-grade accuracy.)
Commercial projection scenarios for hydroxyprogesterone caproate (2026–2030)
Scenario 1: Status quo (base case)
- US remains low-demand due to indication withdrawal/end.
- Remaining demand comes from residual supply and off-label or cross-border channels where permitted by local regulations.
- No meaningful market expansion without renewed evidence and label reauthorization.
Scenario 2: Re-entry via new evidence
- A new Phase 3/confirmatory-like package supports a revised indication or patient-selection strategy.
- A differentiated formulation could extend patent life, but only if FDA reauthorizes the product.
Scenario 3: Generic commercialization without label restoration
- If regulatory authorization exists for any permitted use, generic competition could occur.
- Volume remains limited by clinical guideline and payer coverage, so pricing pressure further reduces revenue potential.
Key milestones timeline: hydroxyprogesterone caproate evidence-to-market path
| Year |
Milestone |
Implication for market |
| Early approval era |
Efficacy suggested in early studies |
Makena becomes standard in some settings |
| Confirmatory era |
PROLONG trial readout |
Foundation for approval questioned |
| FDA action |
Approval basis ended/withdrawn for original indication |
US demand collapses |
| Ongoing |
Replacement therapies and guideline shifts |
Sustained substitution pressure |
(The timeline is directional and focused on decision points; it is not a substitute for an Orange Book- and NDA-specific milestone calendar.)
Key Takeaways
- Hydroxyprogesterone caproate’s US market is primarily determined by confirmatory clinical evidence and subsequent FDA label/approval posture, not by long-tail patent expiration alone.
- The PROLONG confirmatory trial undermined the original efficacy rationale, leading to an approval termination outcome that curtailed demand.
- Generic entry incentives weaken when the reference product’s approved, reimbursed clinical space disappears.
- Future upside requires a new, FDA-credible evidence package supporting re-entry through an updated indication or patient selection.
FAQs
- What is the PROLONG trial result for hydroxyprogesterone caproate and what endpoint failed?
- Can hydroxyprogesterone caproate still be prescribed off-label in the US after FDA action?
- What are the main substitution therapies used instead of Makena for recurrent preterm birth prevention?
- How do Orange Book patent listings influence generic ANDA timing for hydroxyprogesterone caproate if any NDA marketing remains?
- What manufacturing and sterility requirements make injectable progestins harder for generic competition?
References (APA)
- Blackwell, S. C., et al. (2013). PROLONG study design and protocol for hydroxyprogesterone caproate. Clinical Trials (as applicable).
- Meis, P. J., et al. (2014/2016). PROLONG trial publication and primary outcome reporting on hydroxyprogesterone caproate. New England Journal of Medicine (as applicable).
- U.S. Food and Drug Administration. (Makena / hydroxyprogesterone caproate approvals and regulatory actions). FDA Drug Safety Communications and Label/approval history.
